Trial reportSurgery today2007
Neutrophil elastase inhibitor (sivelestat) preserves antitumor immunity and reduces the inflammatory mediators associated with major surgery.
Trial report in Surgery today, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of neutrophil elastase inhibitor in patients undergoing esophagectomy: a systematic review and meta-analysis.World journal of gastroenterology · 2015Pooled it
- The clinical effectiveness of sivelestat in treating sepsis patients with both acute respiratory distress syndrome and septic cardiomyopathy.Journal of cardiothoracic surgery · 2024Trial
- The Neutrophil-NET Axis in Immune Checkpoint Inhibitor Resistance in Non-Small Cell Lung Cancer: Roles, Biomarkers and Therapeutic Opportunities.Biomolecules · 2026Review
- Pharmacological treatment to reduce pulmonary morbidity after esophagectomy.Annals of gastroenterological surgery · 2021Review
- Article
- CXCR2 expression and postoperative complications affect long-term survival in patients with esophageal cancer.World journal of surgical oncology · 2015Article
- Protective effects of sivelestat in a caerulein-induced rat acute pancreatitis model.Inflammation · 2013Article
- Preventive effect of sivelestat on postoperative respiratory disorders after thoracic esophagectomy.Surgery today · 2013Article
- Reduced plasma ghrelin levels on day 1 after esophagectomy: a new predictor of prolonged systemic inflammatory response syndrome.Surgery today · 2013Article
- The effects of the early administration of sivelestat sodium, a selective neutrophil elastase inhibitor, on the postoperative course after radical surgery for esophageal cancer.Surgery today · 2012Article
- Clinical evaluation of sivelestat for acute lung injury/acute respiratory distress syndrome following surgery for abdominal sepsis.Drug design, development and therapy · 2012Article
- Lung injury following acute kidney injury: kidney-lung crosstalk.Clinical and experimental nephrology · 2011Review
- Neutrophil elastase contributes to acute lung injury induced by bilateral nephrectomy.The American journal of pathology · 2010Article
- Impact of perioperative peripheral blood values on postoperative complications after esophageal surgery.Surgery today · 2010Article
- The role of serum interleukin-8 in hepatic resections.Surgery today · 2010Article
- Postoperative management using intensive patient-controlled epidural analgesia and early rehabilitation after an esophagectomy.Surgery today · 2009Article
- Postoperative suppression of inflammatory cytokines after distal gastrectomy in elderly patients.Surgery today · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo examine the effects of the administration of perioperative sivelestat, a selective neutrophil elastase inhibitor, on tumor immunity and inflammatory mediators in patients who undergo major surgery.
methodsThirteen patients admitted to the hospital for elective surgery were equally randomized into one of two groups: the Sivelestat group (n = 6) and the control group (n = 7). Thereafter, the immunosuppressive acidic protein (IAP), serum interleukin-6 (IL-6), and type 1/type 2 T-helper cell balance were all assessed at several time points before and after surgical intervention.
resultsThe serum IL-6 values at 1 and 12 h after surgery and on postoperative days 1 and 3 were all significantly lower in the sivelestat group than in the control group. The IAP values at postoperative days 7 and 28 in the sivelestat group were also significantly lower than those in the control group. There was a significant correlation between the IL-6 level at 1 h after surgery and the IAP level at postoperative days 7 and 28.
conclusionsIn this preliminary study, the perioperative administration of sivelestat was thus suggested to reduce surgical stress by decreasing the cytokine release and preserving the antitumor immunity.
Indexed as
Identifiers
17468814What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.